Business
-
According to Lightlake Therapeutics, the company has signed a contract with a manufacturer for commercial production of its intranasal naloxone for the reversal of opioid overdose. In December 2013, the company announced positive initial results… Read more . . .
-
Otsuka has announced the launch of its new Meptin Swinghaler procaterol hydrochloride DPI for the treatment of asthma and COPD in Japan as of July 2, 2014. The Meptin Swinghaler was approved in Japan in… Read more . . .
-
Vectura has announced a new US partnership for its VR506, which it describes as “an ICS for the treatment of asthma” and as “clinical stage asthma monotherapy delivered using Vectura’s proprietary technology.” Elsewhere, the company… Read more . . .
-
The Australian Research Council (ARC) has awarded a 3-year, $482,738 linkage grant titled “One for all and all for one- Engineering a drug delivery platform for DNA vaccines to the lung” to members of the… Read more . . .
-
Verona Pharma has announced that it will stop development of its VRP700 inhaled antitussive after the drug failed to produce statistically significant reduction in cough frequency compared to placebo in a Phase 2a clinical trial.… Read more . . .
-
Under the terms of a newly reached settlement, Perrigo and Catalent will be able to market limited quantities of their generic version of Teva’s Proair HFA albuterol MDI starting in December 2016. Beginning in July… Read more . . .
-
According to Consort Medical’s financial report for the fiscal year ending April 2014, its Bespak subsidiary is adding a 4,200 sq m facility for the manufacture of a nicotine DPI and a 5,200 sq m… Read more . . .
-
Discovery Laboratories says that it will use the $1.9 million it has received from the National Heart, Lung, and Blood Institute (NHLBI) for a Phase 2a trial of Aerosurf inhaled KL4 surfactant that is already… Read more . . .
-
AstraZeneca has paid $7.25 million up-front with potential milestone payments of up to $225 million for a global licence from Synairgen for its SNG001 inhaled interferon beta for the treatment of viral respiratory tract infections… Read more . . .
-
Aradigm has received a $5 million milestone payment from Grifols as the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial of Pulmaquin inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis gets underway, the company announced.… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland